{"id":"NCT00317226","sponsor":"American Regent, Inc.","briefTitle":"Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease","officialTitle":"Open Label Extension Study Evaluating the Long Term Safety, Tolerability and Efficacy of an Iron Maintenance Dosing Strategy Utilizing Intravenous VIT45 in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06","primaryCompletion":"2007-03","completion":"2007-09","firstPosted":"2006-04-24","resultsPosted":"2015-06-10","lastUpdate":"2018-02-20"},"enrollment":145,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Ferric Carboxymaltose (FCM)","otherNames":[]}],"arms":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the long term safety and tolerability of an iron maintenance dosing strategy utilizing VIT45 in the treatment of anemia of non-dialysis dependent chronic kidney disease (NDD-CKD). This study is a long term extension to protocol 1VIT04004 (NCT00317239).","primaryOutcome":{"measure":"Incidence of Treatment-emergent Adverse Events","timeFrame":"44 week study duration","effectByArm":[{"arm":"Ferric Carboxymaltose (FCM)","deltaMin":84,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":127},"commonTop":["Odema peripheral","Urinary tract infection","Hypertension"]}}